EE03473B1 - Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon - Google Patents

Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon

Info

Publication number
EE03473B1
EE03473B1 EE9700244A EE9700244A EE03473B1 EE 03473 B1 EE03473 B1 EE 03473B1 EE 9700244 A EE9700244 A EE 9700244A EE 9700244 A EE9700244 A EE 9700244A EE 03473 B1 EE03473 B1 EE 03473B1
Authority
EE
Estonia
Prior art keywords
proton pump
pump inhibitor
pharmaceutical composition
composition
ppi
Prior art date
Application number
EE9700244A
Other languages
English (en)
Other versions
EE9700244A (et
Inventor
J. Dave Kaushik
B. Williams James
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9700244A publication Critical patent/EE9700244A/et
Publication of EE03473B1 publication Critical patent/EE03473B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EE9700244A 1995-04-04 1996-03-29 Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon EE03473B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/416,275 US5708017A (en) 1995-04-04 1995-04-04 Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
PCT/US1996/004355 WO1996031213A1 (en) 1995-04-04 1996-03-29 Pharmaceutical composition containing proton pump inhibitors

Publications (2)

Publication Number Publication Date
EE9700244A EE9700244A (et) 1998-04-15
EE03473B1 true EE03473B1 (et) 2001-08-15

Family

ID=23649308

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700244A EE03473B1 (et) 1995-04-04 1996-03-29 Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon

Country Status (29)

Country Link
US (1) US5708017A (et)
EP (1) EP0819004B1 (et)
JP (1) JP4603631B2 (et)
KR (1) KR100419105B1 (et)
CN (1) CN1080119C (et)
AT (1) ATE438380T1 (et)
AU (1) AU703755B2 (et)
BR (1) BR9604803A (et)
CA (1) CA2217515C (et)
CY (1) CY2613B2 (et)
CZ (1) CZ287297B6 (et)
DE (1) DE69637985D1 (et)
DK (1) DK0819004T3 (et)
EA (1) EA000087B1 (et)
EE (1) EE03473B1 (et)
ES (1) ES2329098T3 (et)
HU (1) HU227864B1 (et)
IS (1) IS2706B (et)
MX (1) MX9707694A (et)
NO (1) NO312994B1 (et)
NZ (1) NZ305708A (et)
PL (1) PL183144B1 (et)
PT (1) PT819004E (et)
SI (1) SI0819004T1 (et)
SK (1) SK282872B6 (et)
TR (1) TR199701117T1 (et)
UA (1) UA42061C2 (et)
WO (1) WO1996031213A1 (et)
ZA (1) ZA962657B (et)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
KR100627614B1 (ko) * 1998-04-20 2006-09-25 에자이 가부시키가이샤 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제
NZ510180A (en) 1998-08-10 2002-11-26 Univ California Prodrugs of the pyridyl-methylsulphonyl-benzimidazole type proton pump inhibitors
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
ATE235247T1 (de) * 1998-10-06 2003-04-15 Mars Uk Ltd Verhaltensstörungen beim tier
PL195783B1 (pl) * 1999-02-23 2007-10-31 Merck & Co Inc Preparat farmaceutyczny do doustnego podawania omeprazolu
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
HU229213B1 (en) 1999-10-20 2013-09-30 Eisai R & D Man Co Ltd Bunkyo Ku Method for stabilizing benzimidazole compounds
GB2358136A (en) * 2000-01-15 2001-07-18 Univ Montfort A medicament for the treatment of equine oral stereotypies using a pH regulator
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
NZ522450A (en) * 2000-05-30 2004-07-30 Merial Ltd Methods for prevention of ulcers
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
AU9163701A (en) * 2000-10-27 2002-05-06 Leo Pharma As Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
PT1341524E (pt) * 2000-12-07 2011-12-30 Nycomed Gmbh Preparação farmacêutica na forma de uma pasta compreendendo um ingrediente activo lábil a ácido
WO2002045692A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
US20050019390A1 (en) * 2001-10-26 2005-01-27 John Kohnke Dosage system and dosage vehicle therefor
AUPS244002A0 (en) * 2002-05-20 2002-06-13 John Kohnke Products Pty Ltd Agent delivery system
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004004690A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
ATE323695T1 (de) * 2002-07-19 2006-05-15 Winston Pharmaceuticals Llc Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
WO2004064719A2 (en) * 2003-01-24 2004-08-05 State Of Israel, Ministry Of Agriculture Synergistic compositions and methods for potentiating anti-oxidative activity
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
US20080287502A1 (en) * 2004-03-30 2008-11-20 Dermatrends, Inc. Transdermal Administration of Proton Pump Inhibitors
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN103463096B (zh) * 2006-01-27 2016-03-16 耶鲁大学 胃酸分泌的快速作用抑制剂
CN104825397A (zh) * 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
EP2142432A1 (en) 2007-03-30 2010-01-13 Enterprises International, Inc. Strapping track assembly and method of using the same
CN101980700A (zh) 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
WO2009120885A2 (en) * 2008-03-26 2009-10-01 Taro Pharmaceuticals U.S.A., Inc. Stabilizing lipid compositions for oral pharmaceutical agents
CN106974888B (zh) 2008-09-17 2019-08-02 克艾思马有限公司 药物组合物和相关的给药方法
DE102009018133A1 (de) * 2009-04-15 2010-11-11 Agon Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
GB201306720D0 (en) * 2013-04-12 2013-05-29 Special Products Ltd Formulation
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
DK3386507T3 (da) * 2015-12-08 2023-09-18 Luoda Pharma Ltd Metoder og sammensætninger til behandling af mavesår
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3033065A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
EP3299017A1 (en) * 2016-09-23 2018-03-28 The Boots Company PLC Formulation
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
GB201804621D0 (en) * 2018-03-22 2018-05-09 Bcm Specials Ltd Formulation
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
GB202116644D0 (en) 2021-11-18 2022-01-05 Innovate Pharmaceuticals Ltd Liquid composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
EP0425505B1 (en) * 1988-06-30 1993-03-17 The Upjohn Company Transdermal antisecretory agents for gastrointestinal disease
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs

Also Published As

Publication number Publication date
EE9700244A (et) 1998-04-15
US5708017A (en) 1998-01-13
MX9707694A (es) 1997-12-31
CY2613B2 (en) 2011-04-06
CN1185107A (zh) 1998-06-17
NO312994B1 (no) 2002-07-29
NZ305708A (en) 1999-11-29
HK1004658A1 (en) 1998-12-04
DE69637985D1 (de) 2009-09-17
EP0819004A4 (en) 2006-01-18
EA199700294A1 (ru) 1998-02-26
CZ313597A3 (cs) 1998-04-15
TR199701117T1 (xx) 1998-02-21
NO974589D0 (no) 1997-10-03
SK282872B6 (sk) 2003-01-09
DK0819004T3 (da) 2009-11-30
PL183144B1 (pl) 2002-05-31
WO1996031213A1 (en) 1996-10-10
AU703755B2 (en) 1999-04-01
ES2329098T3 (es) 2009-11-20
KR100419105B1 (ko) 2004-05-31
PL322619A1 (en) 1998-02-02
JP4603631B2 (ja) 2010-12-22
CZ287297B6 (en) 2000-10-11
SK135097A3 (en) 1998-06-03
IS4576A (is) 1997-10-02
IS2706B (is) 2011-01-15
UA42061C2 (uk) 2001-10-15
EP0819004B1 (en) 2009-08-05
HUP9801626A2 (hu) 1999-02-01
ZA962657B (en) 1996-10-09
PT819004E (pt) 2009-10-12
BR9604803A (pt) 1998-06-09
CA2217515A1 (en) 1996-10-10
AU5379796A (en) 1996-10-23
CN1080119C (zh) 2002-03-06
CA2217515C (en) 2005-03-15
KR19980703576A (ko) 1998-11-05
EA000087B1 (ru) 1998-06-25
SI0819004T1 (sl) 2009-12-31
HU227864B1 (en) 2012-05-29
EP0819004A1 (en) 1998-01-21
HUP9801626A3 (en) 2000-06-28
NO974589L (no) 1997-12-03
JPH11503160A (ja) 1999-03-23
ATE438380T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
EE9700244A (et) Prootonpumba inhibiitorit sisaldav farmatseutiline kompositsioon
BG105754A (en) Pharmaceutical composition containing proton pump inhibitors
DK0696921T3 (da) Veterinært præparat indeholdende en protonpumpeinhibitor
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
TNSN98049A1 (fr) Composition pharmaceutique a residence gastrique.
CA2161683A1 (en) Veterinary composition containing a proton pump inhibitor

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name